| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/22/2023 | 68.41% | Cantor Fitzgerald | → $7 | Reiterates | Overweight → Overweight |
| 08/04/2023 | 1704.45% | HC Wainwright & Co. | → $75 | Reiterates | → Buy |
| 08/04/2023 | 68.41% | RBC Capital | $5 → $7 | Maintains | Outperform |
| 08/04/2023 | 405.24% | EF Hutton | → $21 | Reiterates | Buy → Buy |
| 07/10/2023 | 20.3% | RBC Capital | → $5 | Reiterates | Outperform → Outperform |
| 06/28/2023 | 1704.45% | HC Wainwright & Co. | $75 → $75 | Reiterates | Buy → Buy |
| 06/21/2023 | 20.3% | RBC Capital | → $5 | Reiterates | Outperform → Outperform |
| 06/20/2023 | 405.24% | EF Hutton | → $21 | Reiterates | Buy → Buy |
| 05/18/2023 | 68.41% | Cantor Fitzgerald | → $7 | Reiterates | → Overweight |
| 05/18/2023 | 405.24% | EF Hutton | → $21 | Reiterates | Buy → Buy |
| 05/09/2023 | 1704.45% | HC Wainwright & Co. | → $75 | Reiterates | → Buy |
| 05/05/2023 | 405.24% | EF Hutton | → $21 | Reiterates | → Buy |
| 04/18/2023 | 1704.45% | HC Wainwright & Co. | → $75 | Reiterates | → Buy |
| 04/14/2023 | 429.3% | Oppenheimer | → $22 | Reiterates | → Outperform |
| 04/14/2023 | 405.24% | EF Hutton | → $21 | Reiterates | → Buy |
| 03/16/2023 | 1704.45% | HC Wainwright & Co. | → $75 | Reiterates | → Buy |
| 03/10/2023 | 20.3% | RBC Capital | → $5 | Reiterates | → Outperform |
| 03/10/2023 | 405.24% | EF Hutton | → $21 | Reiterates | → Buy |
| 01/19/2023 | 1704.45% | HC Wainwright & Co. | → $75 | Reiterates | → Buy |
| 12/16/2022 | 405.24% | EF Hutton | → $21 | Initiates Coverage On | → Buy |
| 11/16/2022 | 20.3% | RBC Capital | → $5 | Initiates Coverage On | → Outperform |
| 09/21/2022 | 1704.45% | HC Wainwright & Co. | $5 → $75 | Maintains | Buy |
| 08/26/2022 | -15.79% | Oppenheimer | → $3.5 | Initiates Coverage On | → Outperform |
| 08/16/2022 | 20.3% | HC Wainwright & Co. | $10 → $5 | Maintains | Buy |
| 05/04/2022 | 68.41% | Roth Capital | → $7 | Initiates Coverage On | → Buy |
| 08/05/2021 | 140.59% | HC Wainwright & Co. | → $10 | Initiates Coverage On | → Buy |
| 06/28/2021 | 44.36% | Maxim Group | → $6 | Initiates Coverage On | → Buy |
What is the target price for Mind Medicine (MNMD)?
The latest price target for Mind Medicine (NASDAQ: MNMD) was reported by Cantor Fitzgerald on August 22, 2023. The analyst firm set a price target for $7.00 expecting MNMD to rise to within 12 months (a possible 68.41% upside). 23 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Mind Medicine (MNMD)?
The latest analyst rating for Mind Medicine (NASDAQ: MNMD) was provided by Cantor Fitzgerald, and Mind Medicine reiterated their overweight rating.
When is the next analyst rating going to be posted or updated for Mind Medicine (MNMD)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Mind Medicine, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Mind Medicine was filed on August 22, 2023 so you should expect the next rating to be made available sometime around August 22, 2024.
Is the Analyst Rating Mind Medicine (MNMD) correct?
While ratings are subjective and will change, the latest Mind Medicine (MNMD) rating was a reiterated with a price target of $0.00 to $7.00. The current price Mind Medicine (MNMD) is trading at is $4.16, which is within the analyst's predicted range.